16 November 2017

10 Spring Gardens, London, SW1A 2BU

Final agenda

The meeting will start promptly at 10:00 and is expected to finish at approximately 16:00.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Minutes from the last Committee meeting held on 18 October 2017 – Part 1 only (open session)
  5. Appraisal of nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]This topic is to be held in the part 2 session only because the appraisal is being discussed before the CHMP opinion has been issued.
    • 5.1. Declarations of interest – Part 2 only (closed session)
    • 5.2. Introduction by the Chair, Dr Amanda Adler – Part 2 only (closed session)
    • 5.3. Presentation by the lead team – Part 2 only (closed session)
    • 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of autologous chondrocyte implantation with chondrosphere for treating articular cartilage defects [ID851]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 6.3. Presentation by the lead team – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
    1. Appraisal of beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) [ID809]
      • 7.1. Declarations of interest – Part 1 only (open session)
      • 7.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
      • 7.3. Presentation by the Chair, Dr Amanda Adler – Part 1 AND part 2 (open and closed session)
      • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of lenvatinib with everolimus for previously treated advanced renal cell carcinoma [ID1029]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction by the Chair, Dr Amanda Adler – Part 2 only (closed session)
    • 8.3. Presentation by the Chair, Dr Amanda Adler – Part2 only  (closed session)
    • 8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Thursday 4 January 2018, venue TBC.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Thursday 2 November 2017Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Sunah Akhtar.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 19 October 2017 to 02 November 2017
Registration is closed.